

This newsletter summarises final decisions from HTA bodies around the world from March 2024.

These decisions are categorised into one of four groups.

- *Decisions of HTA bodies are categorised according to the type of intervention into Pharmacological, Non-Pharmacological and Diagnostic.*
- *Statements from HTA bodies in the form of guidelines on the management of a disease using specific interventions are included under Other Guidance.*

Click on the category you are interested in to jump to that section

[Pharmacological
Technologies](#)

[Non-pharmacological
Technologies](#)

[Diagnostic
Tests](#)

[Other
Guidance](#)

Within each section the reports have been grouped according to clinical speciality. On the section contents page, there are shortcuts to each clinical speciality and specific report. All tiles are hyperlinked to the report file or to the HTA website.

Here we list a key for the decisions made by the HTA bodies for the reports listed in this newsletter:



The reporting document states that the technology has been approved.



The reporting document states that the technology has not been approved.



The report was terminated, additional details are provided under the icon.



The report was excluded because it is covered by another HTA body in that country.



This is where documentation cannot be translated or it is unclear on the reporting outcome.



This entry includes a note from the report relating to the technology.




This is for reports that do not report a decision but summarises the evidence for the technology.

Pharmacological Technologies



Cancer

- Axicabtagene ciloleucel - France
- Axicabtagene ciloleucel - Scotland
- Daratumumab - Germany
- Durvalumab - Brazil
- Durvalumab - Germany
- Elranatamab - France
- Ibrutinib - Brazil
- Ivosidenib - Scotland
- Lenalidomide & rituximab - Brazil
- Nivolumab - Germany
- Olaparib - Scotland
- Rituximab - Brazil
- Rucaparib - Germany
- Talazoparib - Scotland
- Tebentafusp - Germany
- Trastuzumab deruxtecan - Germany
- Zanubrutinib - Germany




Cardiovascular

- Tafamidis - Brazil



Endocrine

- Fezolinetant - Australia



Gastrointestinal

- Infliximab - Brazil

Genitourinary



- Elugolix/ Estradiol/ Norethisterone acetate - Germany
- Imlifidase - France

Infection



- Fostemsavir trometamol - Brazil
- Gentamicin sulfate + doxycycline - Brazil
- Letermovir - Germany
- Letermovir - Germany
- Maribavir - France
- Nirmatrelvir and ritonavir - Scotland
- Sotrovimab - France

Pharmacological Technologies



Metabolic/Genetic

- Alirocumab - Germany
- Efanesoctocog alfa - France
- Evinacumab - France
- Ivacaftor/tezacaftor/elexacaftor - Germany
- Ivacaftor/tezacaftor/elexacaftor - Germany
- Ivacaftor/tezacaftor/elexacaftor - Germany
- Ivacaftor/tezacaftor/elexacaftor - Germany
- Lanadelumab - Germany
- Maralixibat - France
- Odevixibat - France
- Patisiran - Germany
- Pegunigalsidase alfa - Germany
- Vosoritide - Germany



Musculoskeletal

- Pasireotide pamoate - Brazil
- Pegvisomant - Brazil
- Romosozumab, teriparatide - Brazil

Neurology




- Atogepant - Wales
- Cannabidiol - Germany
- Cannabidiol - Germany
- Cannabidiol - Germany
- Foslevodopa-Foscarbidopa - Scotland
- Satralizumab - Scotland

Respiratory



- Mepolizumab - Brazil
- Omalizumab - Brazil
- Pitolisant - Scotland

Skin



- Tirbanibulin - Australia

Non-pharmacological Technologies



Cancer

- Intraoperative neurophysiological monitoring - Brazil
- Irreversible electroporation - South Korea
- Optune - Canada
- Photodynamic therapy - Brazil



Gastrointestinal

- Endoscopic haemostatic powder - South Korea

Other

- Hyperbariatric oxygen therapy - Spain



Respiratory

- Less invasive surfactant administration - South Korea

Diagnostic Technologies




Blood

- Indocyanine green - Australia



Cancer

- Echobronchoscopy and echoendoscopy - Brazil
- Indocyanine green - Australia
- MRI during radiotherapy - South Korea



Cardiovascular

- Artificial intelligence-based CT Imaging - South Korea
- Artificial intelligence-based diagnostic test - South Korea



Eye

- Systematic screening for diabetic retinopathy - Spain



Gastrointestinal

- Fecal calprotectin - Brazil
- Indocyanine green - Australia



Infection

- Monocyte distribution width - South Korea




Metabolic/Genetic

- Urinary porphobilinogen - Brazil

Musculoskeletal

- HLA-B27 detection - Brazil



Neurology

- Algorithm-Based Alzheimer's Disease Diagnosis-Aided Test - South Korea




Other Guidance



Cancer

- Ciltacabtagene autoleucel - Austria
- Diagnosis and management guidelines - England
- Familial and genetic risk assessment - England
- Pembrolizumab - Austria
- Retifanlimab - Austria
- Tislelizumab - Austria
- Tumor Therapy Fields - Switzerland



Cardiovascular

- Allopurinol - United Kingdom
- Measurement and monitoring of pulmonary arterial pressure using an implanted sensor - Germany




Ear

- Betahistine/cinnarizine +/- dimenhydrinate - Switzerland



Eye

- Clinical protocol and therapeutic guidelines: DR - Brazil



Gastrointestinal

- Tofacitinib and other drugs - Canada

Infection



- Antibiotics - England
- Diagnosis and management guidelines - England
- Management guidelines - England
- Prehospital early warning scores - United Kingdom

Mental Health



- KardiaMobile 6L - United Kingdom
- Patient-reported outcome measures for monitoring primary care - United Kingdom

Metabolic/Genetic



- Clinical protocol and therapeutic guidelines: CF - Brazil

Musculoskeletal



- Intra-articular hyaluronic acid - Canada

Neurology



- Clinical protocol and therapeutic guidelines: MS - Brazil
- Guidance - United States

Other Guidance

Other

- [Diagnosis and management guidelines - England](#)
- [Ketamine - Canada](#)
- [Vital signs monitoring - United Kingdom](#)



Respiratory

- [Aerosol therapy with inhalers - Canada](#)



Surgery

- [Intravenous acetaminophen - Canada](#)
- [Reprocessed single-use semicritical and critical medical devices - Canada](#)

Pharmacological Technologies



France  Axicabtagene ciloleucel Population: Adult 21 March 2024	 For high-grade B-cell lymphoma and diffuse large B-cell lymphoma HAS AP175  Early access authorisation	Scotland  Axicabtagene ciloleucel Population: Adult 11 March 2024	 For relapsed/ refractory diffuse large B-cell lymphoma SMC2628 
Germany  Daratumumab Population: Adult 01 March 2024	 For newly diagnosed multiple myeloma IQWiG A23-127 	Brazil  Durvalumab Population: Unknown 06 March 2024	 For unresectable stage III NSCLC CONITEC 

Pharmacological Technologies



Germany



Durvalumab

Population:
Adult

15 March 2024

For untreated advanced/
unresectable
hepatocellular
carcinoma

IQWiG A23-138



France



Elranatamab

Population:
Adult

28 March 2024

For relapsed/ refractory
multiple myeloma

HAS AP292



Renewal of early access
authorisation

Brazil



Ibrutinib

Population:
Unknown

06 March 2024

For chronic lymphocytic
leukaemia

CONITEC



Recommended for public
consultation with an
unfavorable opinion.

Scotland



Ivosidenib

Population:
Adult

11 March 2024

For newly diagnosed
AML with IDH1-R132
mutation

SMC2615



Pharmacological Technologies



Brazil



Lenalidomide &
rituximab

Population:
Unknown

06 March 2024

For previously treated
follicular lymphoma

CONITEC



Recommended for public
consultation with a
favorable opinion.

Germany



Nivolumab

Population:
Adult and
Adolescent
>12 years old

21 March 2024

For adjuvant, stage IIB
or IIC melanoma

IQWiG A23-94



Scotland



Olaparib

Population:
Adult

11 March 2024

For metastatic
castration-resistant
prostate cancer

SMC2617



Brazil



Rituximab

Population:
Unknown

06 March 2024

For asymptomatic
follicular lymphoma

CONITEC



Recommended for public
consultation with an
unfavorable opinion.

Pharmacological Technologies



Germany  Rucaparib Population: Adult 15 March 2024	Maintenance therapy for advanced high-grade epithelial ovarian cancer <i>IQWiG A23-134</i>  NOT APPROVED	Scotland  Talazoparib Population: Adult 11 March 2024	For BRCA1/2+, HER2-, advanced/metastatic breast cancer <i>SMC2607</i>  APPROVED
Germany  Tebentafusp Population: Adult 01 March 2024	For uveal melanoma <i>IQWiG A23-128</i>  APPROVED	Germany  Trastuzumab deruxtecan Population: Adult 01 March 2024	For advanced NSCLC with hEGFR2 mutation <i>IQWiG A23-115</i>  NOT APPROVED

Pharmacological Technologies



Cancer



Cardiovascular

Germany



Zanubrutinib

Population:
Adult

15 March 2024

For relapsed/ refractory
follicular lymphoma



Brazil



Tafamidis

Population:
Adult
>60 years

06 March 2024

For transthyretin
amyloid
cardiomyopathy

CONITEC



Recommended for public
consultation with an
unfavorable opinion.

Pharmacological Technologies



Endocrine

Australia



Fezolinetant

Population:
Adult

06 March 2024



For moderate to severe
menopausal vasomotor
symptoms

TGA



APPROVED



Gastrointestinal

Brazil



Infliximab

Population:
Adult

06 March 2024



For refractory moderate
to severe Crohn's
disease

CONITEC



EXCLUDED

Pharmacological Technologies



Genitourinary

Germany



Elugolix/ Estradiol/
Norethisterone
acetate

Population:
Adult

01 March 2024

For persistent
endometriosis

IQWiG A23-117



Brazil



Fostensavir
trometamol

Population:
Adult

06 March 2024

For multidrug-resistant
HIV

CONITEC



France



Imlifidase

Population:
Adult

21 March 2024

For hyperimmunised
patients awaiting kidney
transplantation

HAS AP162



Renewed early access
authorisation

Brazil



Gentamicin sulfate +
doxycycline

Population:
Unknown

06 March 2024

For human brucellosis

CONITEC



Recommended for public
consultation with a
favorable opinion.

Pharmacological Technologies



Infection

Germany



Letermovir

For prophylaxis against
CMV after stem cell
transplant

IQWiG A23-139



Population:
Adult

15 March 2024

Germany



Letermovir

For prophylaxis against
CMV after kidney
transplant



Population:
Adult

15 March 2024

France



Maribavir

For cytomegalovirus
infection and/or
refractory disease

HAS AP166



Early access authorisation

Population:
Adult and
Adolescent
>12 years

20 March 2024

Scotland



Nirmatrelvir and
ritonavir

For COVID-19

SMC2557



Population:
Adult

13 March 2024

Pharmacological Technologies



Infection

France



Sotrovimab

For COVID-19

HAS AP144



Renewed early access
authorisation

08 March 2024



Genetic/Metabolic

Germany



Alirocumab

For heterozygous
familial
hypercholesterolaemia

IQWiG A23-136



Population:
Children and
Adolescent
>8 years old

15 March 2024

France



Efanesoctocog alfa

For severe haemophilia
A without factor VIII
inhibitors

HAS AP287



Population:
Adult and Children

08 March 2024

Early access authorisation

Pharmacological Technologies



Genetic/Metabolic

France



Evinacumab

For homozygous
familial
hypercholesterolaemia

HAS AP317



Early access authorisation

28 March 2024

Germany



Ivacaftor/ tezacaftor/
elexacaftor

Population:
Children
2 to 5 years old

01 March 2024

For cystic fibrosis,
heterozygous F508del
and RF mutations

IQWiG A23-125



Germany



Ivacaftor/ tezacaftor/
elexacaftor

For cystic fibrosis,
homozygous F508del
mutation

IQWiG A23-123



Population:
Children
2 to 5 years old

01 March 2024

Germany



Ivacaftor/ tezacaftor/
elexacaftor

Population:
Children
2 to 5 years old

01 March 2024

For cystic fibrosis,
heterozygous F508del
and MF mutations

IQWiG A23-122



Pharmacological Technologies



Genetic/Metabolic

Germany



Ivacaftor/ tezacaftor/
elixacaftor

For cystic fibrosis,
heterozygous F508del
and other/unknown
mutations

IQWiG A23-126



Population:
Children
2 to 5 years old

01 March 2024

Germany



Ivacaftor/ tezacaftor/
elixacaftor

For cystic fibrosis,
heterozygous F508del
and gating mutations

IQWiG A23-124



Population:
Children
2 to 5 years old

01 March 2024

Germany



Lanadelumab

For hereditary
angioedema


IQWiG A23-135



Population:
Children
2 to 12 years old

15 March 2024

France



Maralixibat

For cholestatic pruritus
in Alagille syndrome

HAS AP302



Population:
Adult, Adolescent
and Children
>2 months

12 March 2024

Renewed early access
authorisation

Pharmacological Technologies



Genetic/Metabolic

France



Odevixibat

For cholestatic pruritus
in Alagille syndrome

HAS AP336



Renewed early access
authorisation

Population:
Adult, Adolescent
and Children
>6 months

12 March 2024

Germany



Patisiran

For hereditary
transthyretin
amyloidosis with
polyneuropathy

IQWiG A23-118



Population:
Adult

01 March 2024

Germany



Pegunigalsidase alfa

For Fabry disease

IQWiG A23-95



Population:
Adult

21 March 2024

Germany



Vosoritide

For achondroplasia

IQWiG A23-116



Population:
Children

01 March 2024

Pharmacological Technologies



Musculoskeletal

Brazil



Pasireotide pamoate

Population:
Unknown

06 March 2024

For acromegaly

CONITEC

NOT APPROVED

Recommended for public consultation with an unfavorable opinion.

Brazil



Pegvisomant

Population:
Unknown

06 March 2024

For acromegaly

CONITEC

NOT APPROVED

Recommended for public consultation with an unfavorable opinion.

Brazil



Romosozumab, teriparatide

Population:
Unknown

06 March 2024

For severe osteoporosis

CONITEC

NOTE FROM REPORT

Additional information requested

Pharmacological Technologies



Neurology

Wales



Atogepant

For prophylaxis of
episodic migraine

AWTTC 3689



21 March 2024

Germany



Cannabidiol

For tuberos sclerosis

IQWiG A23-121



Population:
Adult, Adolescent
and Children
>2 years old

01 March 2024

Germany



Cannabidiol

For Lennox-Gastaut
syndrome

IQWiG A23-120



Population:
Adult, Adolescent
and Children
>2 years old

01 March 2024

Germany



Cannabidiol

For Dravet syndrome

IQWiG A23-119




Population:
Adult, Adolescent
and Children
>2 years old

01 March 2024

Pharmacological Technologies



Neurology



Skin

Scotland



Foslevodopa-
Foscarbidopa

Population:
Unknown

11 March 2024

For advanced levodopa-
responsive Parkinson's
disease

SMC2574



Australia



Tirbanibulin

Population:
Adult

06 March 2024

For non-hyperkeratotic,
nonhypertrophic actinic
keratosis of the face or
scalp

TGA



Scotland



Satralizumab

Population:
Adult and
Adolescent
>12 years old

11 March 2024

For neuromyelitis optica
spectrum disorders,
AQP4-IgG seropositive

SMC2663



Pharmacological Technologies



Respiratory

Brazil  Mepolizumab Population: Adolescent 6 to 17 years old 06 March 2024	For severe refractory eosinophilic asthma CONITEC APPROVED	Brazil  Omalizumab Population: Unknown 06 March 2024	For severe uncontrolled allergic asthma CONITEC TERMINATED
Scotland  Pitolisant Population: Adult 11 March 2024	For obstructive sleep apnoea SMC2662 TERMINATED		

Non-pharmacological Technologies



Cancer

Brazil



Intraoperative
neurophysiological
monitoring

Population:
Unknown

08 March 2024

For tumour excision
surgery of
cerebellopontine angle
cancer

CONITEC



South Korea



Irreversible
electroporation

Population:
Unknown

March 2024

For kidney cancer

NECA



Canada



Optune

Population:
Adult

March 2024

For newly diagnosed
glioblastoma multiforme

CADTH OP0554-000



Brazil



Photodynamic
therapy

Population:
Unknown

08 March 2024

For non-melanoma,
superficial and nodular
basal cell skin
carcinoma

CONITEC



Recommended for public
consultation with a
favorable opinion.

Non-pharmacological Technologies



Gastrointestinal



Respiratory

South Korea  Endoscopic haemostatic powder Population: Unknown March 2024	 For non-varicose or gastrointestinal bleeding after endoscopic procedures NECA  APPROVED March 2024	South Korea  Less invasive surfactant administration Population: Children Neonates March 2024	 For neonatal respiratory distress syndrome NECA  APPROVED March 2024
--	--	--	---

Non-pharmacological Technologies

Other

Spain



Hyperbariatric oxygen therapy

Population:
Unknown

March 2024

For various diseases

AQuAS

 NOT APPROVED

Diagnostic Technologies



Cancer

Brazil



Echobronchoscopy and echoendoscopy

Population: Unknown

08 March 2024

For lung cancer

CONITEC

APPROVED

Australia



Indocyanine green

Population: Adult

07 March 2024

For visualisation of lymph nodes for cervical and uterine tumours

TGA

APPROVED

South Korea



MRI during radiotherapy

Population: Unknown

March 2024

For cancer

NECA

APPROVED

Diagnostic Technologies



Blood

Australia




Indocyanine green

Population:
Adult, Adolescent
and Children

07 March 2024

For visualisation of
blood flow and tissue
perfusion

TGA



Cardiovascular

South Korea



Artificial
intelligence-based
CT Imaging

Population:
Adult
>19 years old

March 2024

For large vessel
occlusion screening
during acute stroke

NECA



South Korea



Artificial
intelligence-based
diagnostic test

Population:
Unknown

March 2024

For paroxysmal atrial
fibrillation

NECA



Diagnostic Technologies



Eye



Gastrointestinal

Spain



Systematic
screening for
diabetic retinopathy

Population:
Adult

March 2024

For diabetic retinopathy

AQuAS



Brazil



Fecal calprotectin

Population:
Unknown

08 March 2024

For monitoring Crohn's
disease

CONITEC



Australia



Indocyanine green

Population:
Adult and
Adolescent

07 March 2024

For visualisation of
extrahepatic biliary
ducts

TGA



Diagnostic Technologies



Infection



Genetic/Metabolic

South Korea



Monocyte
distribution width

Population:
Adult

March 2024

For sepsis

NECA



Brazil



Urinary
porphobilinogen

Population:
Unknown

08 March 2024

For diagnosis or
prognosis of acute
hepatic porphyrias

CONITEC



Diagnostic Technologies



Musculoskeletal

Brazil



HLA-B27 detection

Population:
Unknown

08 March 2024

For assessment of axial
spondyloarthritis

CONITEC



Neurology

South Korea



Algorithm-Based
Alzheimer's Disease
Diagnosis-Aided
Test

Population:
Unknown

March 2024

For Alzheimer's Disease

NECA



Other Guidance



Cancer

Austria  Ciltacabtagene autoleucel Population: Adult 21 March 2024	For relapsed/ refractory multiple myeloma AIHTA 166 EVIDENCE REVIEW	England  Diagnosis and management guidelines Population: Unknown 08 March 2024	For NSCLC NICE NG122 EVIDENCE REVIEW
England  Familial and genetic risk assessment Population: Adult 21 March 2024	For ovarian cancer NICE NG241 EVIDENCE REVIEW	Austria  Pembrolizumab Population: Adult and Adolescent >12 years 21 March 2024	For resectable NSCLC AIHTA 167 EVIDENCE REVIEW

Other Guidance



Cancer

Austria



Retifanlimab

Population:
Adult

21 March 2024



For metastatic or recurrent advanced Merkel cell carcinoma

AIHTA 165



Austria



Tislelizumab

Population:
Adult

21 March 2024



For advanced/metastatic non-squamous NSCLC

AIHTA 164



Switzerland



Tumor Therapy Fields

Population:
Adult

15 March 2024




For glioblastoma

FOPH



Other Guidance



Cardiovascular

United Kingdom



Allopurinol

Population:
Unknown

March 2024

For ischaemic heart
disease

NIHR



EVIDENCE REVIEW

Switzerland



Betahistine/
cinnarizine +/-
dimenhydrinate

Population:
Adult

08 March 2024

For Ménière's disease/
syndrome, vestibular
vertigo and/or tinnitus

FOPH



EVIDENCE REVIEW

Germany



Measurement and
monitoring of
pulmonary arterial
pressure using an
implanted sensor

Population:
Adult

04 March 2024

For stage NYHA III heart
failure

IQWiG D23-02



EVIDENCE REVIEW

Other Guidance



Eye

Brazil




Clinical protocol and
therapeutic
guidelines: DR

Population:
Unknown

08 March 2024

For diabetic retinopathy

CONITEC



Gastrointestinal

Canada



Tofacitinib and other
drugs

Population:
Adult

March 2024

For ulcerative colitis

CADTH OS0003-000



Other Guidance



Infection

England  Antibiotics Population: Children Neonates 19 March 2024	 For prevention and treatment of neonatal infection NICE NG195  EVIDENCE REVIEW	England  Diagnosis and management guidelines Population: Adult, Adolescent and Children 19 March 2024	 For meningitis and meningococcal disease NICE NG240  EVIDENCE REVIEW
England  Management guidelines Population: Adult, Adolescent and Children 13 March 2024	 For COVID-19 NICE NG191  EVIDENCE REVIEW	United Kingdom  Prehospital early warning scores Population: Adult March 2024	 For diagnosis of sepsis NIHR  EVIDENCE REVIEW

Other Guidance



Mental Health

United Kingdom



KardiaMobile 6L

Population:
Adult

March 2024

To measure QT interval
with antipsychotic
medication

NIHR



EVIDENCE REVIEW



Genetic/Metabolic

Brazil



Clinical protocol and
therapeutic
guidelines: CF

Population:
Unknown

08 March 2024

For cystic fibrosis

CONITEC



EVIDENCE REVIEW

United Kingdom



Patient-reported
outcome measures
for monitoring
primary care

Population:
Adult

March 2024

For depression

NIHR



EVIDENCE REVIEW

Other Guidance



Musculoskeletal



Neurology

Canada



Intra-articular
hyaluronic acid

Population:
Adult

March 2024

For osteoarthritis of the
hip, glenohumeral, or
ankle joints

CADTH RC1528-000

EVIDENCE REVIEW

Brazil



Clinical protocol and
therapeutic
guidelines: MS

Population:
Unknown

08 March 2024

For multiple sclerosis

CONITEC

EVIDENCE REVIEW

United States



Guidance

Population:
Children and
Adolescent

25 March 2024

For ADHD diagnosis
and treatment

AHRQ

EVIDENCE REVIEW

Other Guidance



Respiratory

Canada



Aerosol therapy with inhalers

Population:
Adult
Adults and older adults

March 2024

For mechanical ventilation

CADTH RC1529-000



Surgery

Canada



Intravenous acetaminophen

Population:
Adult

March 2024

For opioid sparing in surgery

CADTH RC1530-000



Canada



Reprocessed single-use semicritical and critical medical devices

Population:
Unknown

March 2024

For surgery

CADTH RC1511-000



Other Guidance

Other

England



Diagnosis and management guidelines

Population:
Adult and Adolescent
≥16 years old

06 March 2024

For vitamin B12 deficiency

NICE NG239



Canada



Ketamine

Population:
Adult

March 2024

For substance abuse disorders

CADTH RC1523-000



United Kingdom



Vital signs monitoring

Population:
Adult

March 2024

To identify deterioration of patients in the general hospital ward

NIHR



About Us

Crystallise provides an innovative approach to identify and synthesise information, using AI to automate processes and assist our experts to produce deliverables that provide real value to clients.

Our team of researchers, medical writers and copy-editors deliver strategically-relevant and comprehensive written reports as well as visually informative summary slide decks, to suit internal business development, market access, journal publication and health technology assessment submissions.

REVIEWS

Systematic Literature Reviews
Global Value Dossiers
Narrative Reviews
Rapid Reviews
Targeted Reviews

HEALTH ECONOMICS

Return on Investment
Network Meta-Analysis
Budgetary Impact Analysis
Cost-effectiveness Analysis

ACTUARIAL

Risk Management
Pricing & Reserving

MODELLING

Mortality and Morbidity Modelling
Synthetic Sample Generation
Infectious Disease Modelling

[To provide feedback on the HTAngel newsletter, click here.](#)

[To unsubscribe, click here.](#)

Registered address

17 High Street,
Stanford-le-Hope,
Essex, SS17 0HD
+44 (0)1375 517878

Company No: 7980921

Data Protection Act Registration Number: Z3363643

Websites:

www.crystallise.com

www.heoro.com

www.evidencemapper.co.uk